Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leukemia treatment showdown: which works best?

NCT ID NCT02938858

Knowledge-focused Sponsor: Groupe Francophone des Myelodysplasies Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This registry study follows 400 patients with a specific type of leukemia (non-high-risk APL) who are 70 or younger. It compares two standard treatments: ATRA plus chemotherapy versus ATRA plus arsenic trioxide. The goal is to see which approach leads to better long-term outcomes and fewer side effects, helping doctors make informed treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ATRA plus chemotherapy or ATRA plus arsenic trioxide (ATO)
What this could lead to
If successful, this registry could help doctors choose the best first-line treatment for non-high-risk APL, improving survival and reducing side effects.
What could go wrong
This is an observational registry, not a controlled trial, so results may be influenced by treatment choices. It does not test a new drug, so no direct breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

400 people

The number who actually took part.

Start date

Oct 2015

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

French patients with newly-diagnosed de novo or therapy-related non-high-risk APL (White Blood Count \< 10000/μl) aged ≤ 70 years.

Ages

Up to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly-diagnosed APL (either de novo or therapy-related) based on cytologic criteria and confirmed by the presence of the t(15;17) translocation and/or by the detection of the fusion transcript PML/RARα. * Non-high-risk APL (White Blood Count \< 10000/μl at presentation) * Age ≤ 70 years Exclusion Criteria: * Relapsed APL * Newly-diagnosed High-risk APL (White Blood Count \> 10000/μl at presentation) * Age \> 70 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute promyelocytic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute promyelocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute promyelocytic leukemia

Contacts and locations

Locations

  • CH Dr Schaffner

    Lens, 62307, France

  • CHR Metz-Thionville - Hôpital de Marcy

    Metz, 57085, France

  • CHRU de Brest - Pédiatrie Spécialisée

    Brest, 29609, France

  • CHU Bordeaux Pellegrin enfant

    Bordeaux, 33076, France

  • CHU Estaing

    Clermont-Ferrand, 63100, France

  • CHU Hôpital Sud - service Hémato-oncologie Pédiatrique

    Rennes, 35203, France

  • CHU Hôtel Dieu

    Nantes, 44035, France

  • CHU Saint Eloi

    Montpellier, 34095, France

  • CHU de Grenoble

    Grenoble, 38043, France

  • Centre Henri Becquerel

    Rouen, 76038, France

  • Centre Hospitalier V. Dupouy

    Argenteuil, 95107, France

  • Centre Hospitalier d'Aix en Provence

    Aix-en-Provence, 13616, France

  • Chru - Hopital Claude Huriez

    Lille, 59037, France

  • Chu Timone

    Marseille, 13385, France

  • Groupe Hospitalier SUD

    Amiens, 80054, France

  • Hopital Andre Mignot

    Le Chesnay, 78150, France

  • Hôpital Henri Mondor

    Créteil, 94100, France

  • Hôpital Jean Minjoz

    Besançon, 25030, France

  • Hôpital Necker

    Paris, 75015, France

  • Hôpital Robert Debré

    Paris, 75019, France

  • Hôpital TROUSSEAU

    Paris, 75012, France

  • Hôpital V. Provo

    Roubaix, 59056, France

  • Hôpital de la Source

    Orléans, 45100, France

  • Hôpital universitaire Dupuytren

    Limoges, 87042, France

  • IUCT Oncopole

    Toulouse, 31059, France

  • Institut Paoli Calmettes

    Marseille, 13273, France

  • Institut de Cancerologie de La Loire

    Saint-Priest-en-Jarez, 42270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.